N-(4-Hydroxyphenyl)retinamide Induces Apoptosis of Malignant Hemopoietic Cell Lines Including Those Unresponsive to Retinoic Acid

Cancer Research

Volumn 53, Issue 24, 1993, Pages 6036-6041

  Formelli, Franca ^c   Costa, Alberto ^c   Grignani, Fausto ^b   Veronesi, Umberto ^b   Menard, Sylvie ^a  

^a Divisions of Experimental Oncology A ^*  (France)

^b UNIVERSITY OF PERUGIA   (Italy)

^c EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER GROWTH; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; CELL CYCLE; CELL DIVISION; DNA; DRUG RESISTANCE; FENRETINIDE; HUMAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; SUPPORT, NON-U.S. GOV'T; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0027332981     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Smith, M. A. Parkinson, D. R. Cheson, B.D. and Friedman, M. A. Retinoids in cancer therapy. J. Clin. Oncol. 10: 839-864, 1992.
2. Sporn, M. B. and Newton, D. L. Chemoprevention of cancer with retinoids. Fed. Proa, 38: 2528-2534, 1979.
3. Dillehay, D. L. Walia, A. S. and Lamon, E. W. Effects of retinoids on macrophage function and IL-1 activity. J. Leukocyte Biol. 44: 353-360, 1988.
4. Jang, X. L. Dillehay, D. L. Everson, M. P. Tilden, A. B. and Lamon, E. W. Potentiation of IL-2-induced T-cell proliferation by retinoids. Int. J. Immunopharma-col. 14: 195-204, 1992.
5. Dowlatshahi, K. Mehta, R. G. Thomas, C. F. Dinger, N. M. and Moon, R. C. Therapeutic effects of N-(4-hydroxyphenyl) retinamide on N-methyl-N-nitrosurea induced rat mammary cancer. Cancer Lett. 47: 187-192, 1989.
6. Moon, R. C. Kelloff, G. J. Detrisac, C. J. Steele, V. E. Thomas, C. F. and Sigman, C. C. Chemoprevention of NMU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res. 12: 1147-1153, 1992.
7. Moon, R. C. Mehta, R. G. and Detrisac, C. J. Retinoids as chemopreventive agents for breast cancer. Cancer Detect. Prev. 16: 73-79, 1992.
8. Pollard, M. and Luckert, P. H. The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarcinoma-III cells in Lobund-Wistar rats. Cancer Lett. 59: 159-163, 1991.
9. Dillehay, D. L. Shealy, F Y, and Lamon, E. W. Inhibition of Moloney murine lymphoma and sarcoma growth in vivo by dietary retinoids. Cancer Res. 49: 44-50, 1989.
10. Bhatnagar, R. Abou-Issa, H. Curley, R. W. Jr. Koolemans-Beynen, A. Moesch-berger, M. L. and Webb, T. E. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate. Biochem. Pharmacol. 41: 1471-1477, 1991.
11. Meyskens, F L. Alberts, D. S. and Salmon, S. E. Effect of 13-cis-retinoic acid and 4-hydroxyphenyl-all-trans-retinamide on human tumor colony formation in soft agar. Int. J. Cancer, 32: 295-299, 1983.
12. Fontana, J. A. Reppucci, A. Durham, J. P. and Miranda, D. Correlation between the induction of leukemic cell differentiation by various retinoids and modulation of protein synthesis. Cancer Res. 46: 2468-2473, 1986.
13. Evans, R. The steroid and thyroid hormone receptorsuperfamily. Science (Washington DC), 240: 889-895, 1988.
14. Bunk, M. J. Kinahan, J. J. and Sarkar, N. H. Biotransformation and protein binding of N-(4-hydroxyphenyl)retinamide in murine mammary epithelial cells. Cancer Lett. 26: 319-326, 1985.
15. zichetta, M. and Veronesi, U. Long term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur. J. Cancer, 27: 1127-1131, 1991.
16. Peng, Y. M. Dalton, W S. Alberts, D. S. Xu, M. J. Lim, H. and Meyskens, F L. Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int. J. Cancer, 43:22-26, 1989 and 44: 567, 1989 (correction).
17. Veronesi, U. De Palo, G. Costa, A. Formelli, F. Marubini, E. and Del Vecchio, M. Chemoprevention of breast cancer with retinoids. J. Natl. Cancer Inst. 12: 93-97, 1992.
18. Chiesa, F. Tradati, N. Marazza, M. Rossi, N. Boracchi, P. Mariani, L. Clerici, M. Formelli, F. Barzan, L. Carrassi, A. Pastorini, A. Camerini, T. Giardini, R. Zurrida, S. Minn, F L. Costa, A. De Palo, G. and Veronesi, U. Prevention of local relapses and new localizations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Eur. J. Cancer, 28B: 97-102, 1992.
19. Warrel, R. Frankel, S. Miller, W. Scheiberg, D. Itri, L. Hittleman, W. Vyas, R. Andreef, M. Tafuri, A. Jakuboski, A. Gabrilove, J. Gordon, M. and Dmitrovsky, E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans retinoic acid). N. Engl. J. Med. 324: 1385-1393, 1991.
20. Chen, Z. X. Xue, Y Q. Zang, R. Tao, R. F. Xia, X. M. Li, C. Wang, W., Zu, W.Y. Yao, X. Z. and Ling, B. J. A clinical and experimental study on all-trans retinoic acid treated acute promyelocytic leukemia patients. Blood, 78: 1413-1419, 1991.
21. Hecht, B. K. Epstei, A. L. Berger, C. S. Kaplan, H. S. and Hecht, F Histiocytic lymphoma cell lines: immunologic and cytogenetic studies. Cancer Genet. Cytogenet. 14: 205-218, 1985.
22. Dyer, M. J. S. Fischer, P. Nacheva, E. Labastide, W. and Karpas, A. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t(14;18) and t(4;ll) chromosomal translocations. Blood, 75: 709-714, 1990.
23. Kluin-Nelemans, H. C. Limpens, J. Meerabux, J. Beverstock, G. C. Jansen, J. H. deJong, D. and Kluin, P. M. A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18Xq32M). Leukemia (Baltimore), 5: 221-224, 1991.
24. Robertson, K. A. Emani, B. and Collins, S. T. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood, 80: 1885-1889, 1992.
25. Lanotte, M. Martin-Thouvenin, V, Najiman, S. Ballerini, P. Valensi, F. and Bergen, R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood, 77: 1080-1086, 1991.
26. Dermine, S. Grignani, F. Clerici, M. Nervi, C. Sozzi, G. Talamo, G. P. Marchesi, E. Formelli, R. Parmiani, G. Pelicci, P. G. and Gambacorti-Passerini, C. The occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB306 is associated with altered expression of the pml/RAR protein. Blood, 52:1573-1577, 1993.
27. Aiello, A. Delia, D. Borrello, M. G. Biassoni, D. Giardini, R. Fontanella, E. Pezzella, R. Pulford, K. Pierotti, M. and Delia Porta, G. Flow cytometric detection of the mitochondrial bcl-2 protein in normal and neoplastic human lymphoid cells. Cytometry, 13: 502-509, 1992.
28. Bissonnette, R. P. Echeverri, F. Mahboubi, A. and Green, D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature (Lond.), 359: 552-554, 1992.
29. Gavrieli, Y. Sherman, Y, and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119: 493-501, 1992.
30. Formelli, F. Carsana, R. Costa, A. Buranelli, R. Campa, T, Dossena, G. Magni, A. and Pizzichetta, M. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res. 49: 6149-6152, 1989.
31. Nicoletti, I. Migliorati, G. Pagliacci, M. C. Grignani, R. and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
32. Kerr, J. R R. and Harmon, B. V. Definition and incidence of apoptosis: an historical perspective. In: L. D. Tomei and R O. Cope (eds.), Apoptosis: The Molecular Basis of Cell Death, pp. 5-30. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1991.
33. Bursch, W. Oberhammer, R, and Schulte-Herman, R. Cell death by apoptosis and its protective role against disease. Trends Pharmacol. Sci. 13: 245-251, 1992.
34. Barry, M. A. Behnke, C. A. and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40: 2353-2362, 1990.
35. Yonish-Rouach, E. Resnitzky, D. Lotem, J. Sachs, L. Kimchi, A. and Oren, M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
36. Korsmeyer, S. Bcl-2 initiates anew category of oncogenes: regulators of cell death. Blood, 80: 879-886, 1992.
37. Martin, S. J. Bradley, J. G. and Cotter, T. G. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin. Exp. Immunol. 79: 448-453, 1990.
38. Robertson, K. A. Emami, B. Mueller, L. M. and Collins, S. J. Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells. Mol. Cell Biol. 12: 3743-3749, 1992.
39. Muindi, J. R. R., Frankel, S. R. Huselton, C. De Grazia, R. Garland, W A. Young, C. W. and Warrel, R. P. Jr. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 52: 2138-2142, 1992.